HARMONY BIOSCIENCES TO HOST FIRST INVESTOR DAY ON OCTOBER 1, 2024

Rhea-AI Summary

Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) will host its first Investor Day on October 1, 2024, at 8:30 a.m. ET in New York City. The event will showcase the company's robust, late-stage pipeline to investors and research analysts. Key highlights include:

• New data on pitolisant for idiopathic hypersomnia (IH)
• Updates on pitolisant-HD development program
• New data on BP1.15205, a potential best-in-class orexin-2 agonist
• Scientific rationale for ZYN002 and EPX100 in Phase 3 trials
• Market potential for late-stage pipeline assets

The company's portfolio now includes three orphan/rare CNS franchises, each with potential peak sales of $1B - $2B. Investors can attend in person or virtually by registering through Harmony's Investor Relations.

PLYMOUTH MEETING, Pa., Sept. 26, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), will provide an overview of its robust, late-stage pipeline at an in-person Investor Day at 8:30 a.m. ET on October 1 in New York City. Members of Harmony's senior leadership team along with therapeutic area key opinion leaders will present to investors and research analysts the following:

• Highlights of the company's late-stage pipeline with key program updates, including:

New data on pitolisant in idiopathic hypersomnia (IH)

Update on pitolisant-HD development program

New data on BP1.15205, a potential best in class orexin-2 agonist

• Scientific rationale for therapeutic efficacy based on mechanisms of action for ZYN002 and EPX100, both in registrational Phase 3 trials
  
  
• Market potential for late-stage pipeline assets following recent acquisitions; portfolio now includes three orphan/rare CNS franchises, each with potential peak sales opportunities of $1B - $2B

The Harmony Investor Day presentation will be made available following the conclusion of the event on the Investors page of the Harmony Biosciences website. Investors interested in attending the event should contact Brennan Doyle at Harmony Investor Relations at bdoyle@harmonybiosciences.com or register here to attend in person or participate virtually. Space is limited.

About Harmony Biosciences 

Harmony Biosciences is a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases who have unmet medical needs. Driven by novel science, visionary thinking, and a commitment to those who feel overlooked, Harmony Biosciences is nurturing a future full of therapeutic possibilities that may enable patients with rare neurological diseases to truly thrive. Established by Paragon Biosciences, LLC, in 2017 and headquartered in Plymouth Meeting, PA, we believe that when empathy and innovation meet, a better future can begin; a vision evident in the therapeutic innovations we advance, the culture we cultivate, and the community programs we foster. For more information, please visit www.harmonybiosciences.com.

Forward Looking Statement:

This presentation includes forward‐looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in these materials or elsewhere, including statements regarding Harmony Biosciences Holdings, Inc.'s (the "Company") future financial position, business strategy and plans and objectives of management for future operations, should be considered forward-looking statements. Forward-looking statements use words like "believes," "plans," "expects," "intends," "will," "would," "anticipates," "estimates," "may," "could," "might," "continue," "potential," and similar words or expressions in discussions of the Company's future operations, financial performance or the Company's strategies, but the absence of these words does not mean that a statement is not forward-looking. These statements are based on current expectations or objectives that are inherently uncertain. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expressed or implied forwarding-looking statements, including, but not limited to the risk factors discussed under the caption "Risk Factors" in the Company's Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (the "SEC") on February 22, 2024 and its other filings with the SEC. While the Company may elect to update such forward-looking statements at some point in the future, it disclaims any obligation to do so, even if subsequent events cause its views to change.

This presentation includes information related to market opportunity as well as cost and other estimates obtained from internal analyses and external sources. The internal analyses are based upon management's understanding of market and industry conditions and have not been verified by independent sources. Similarly, the externally sourced information has been obtained from sources the Company believes to be reliable, but the accuracy and completeness of such information cannot be assured. Neither the Company, nor any of its respective officers, directors, managers, employees, agents, or representatives, (i) make any representations or warranties, express or implied, with respect to any of the information contained herein, including the accuracy or completeness of this presentation or any other written or oral information made available to any interested party or its advisor (and any liability therefore is expressly disclaimed), (ii) have any liability from the use of the information, including with respect to any forward-looking statements, or (iii) undertake to update any of the information contained herein or provide additional information as a result of new information or future events or developments.

Harmony Biosciences Investor Contact:
Brennan Doyle
484-539-9700
bdoyle@harmonybiosciences.com

Harmony Biosciences Media Contact:
Cate McCanless
202-641-6086
cmccanless@harmonybiosciences.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/harmony-biosciences-to-host-first-investor-day-on-october-1-2024-302259359.html

SOURCE Harmony Biosciences

FAQ

When and where is Harmony Biosciences (HRMY) hosting its first Investor Day?

Harmony Biosciences (HRMY) is hosting its first Investor Day on October 1, 2024, at 8:30 a.m. ET in New York City.

What will Harmony Biosciences (HRMY) present at its Investor Day?

Harmony Biosciences (HRMY) will present an overview of its late-stage pipeline, including new data on pitolisant for idiopathic hypersomnia, updates on pitolisant-HD, new data on BP1.15205, and scientific rationale for ZYN002 and EPX100 in Phase 3 trials.

How many orphan/rare CNS franchises does Harmony Biosciences (HRMY) now have in its portfolio?

Harmony Biosciences (HRMY) now has three orphan/rare CNS franchises in its portfolio, each with potential peak sales opportunities of $1B - $2B.

How can investors participate in Harmony Biosciences' (HRMY) Investor Day?

Investors can attend Harmony Biosciences' (HRMY) Investor Day in person or participate virtually by registering through the company's Investor Relations.